This week, I’m rerunning some popular posts before the Labor Day weekend. Click here to see the original post and comments from May 2018. Note that the data from this post were provided to me by the Health Resources and Services Administration (HRSA)!
ICYMI, be sure to read yesterday's New York Times article: A Little-Known Windfall for Some Hospitals, Now Facing Big Cuts
The 340B Drug Pricing Program continues to expand at double-digit rates. Our research reveals that these discounted sales hit a record $19.3 billion in 2017.
What’s more, we found that since 2014, purchases under the program have grown at an average rate of 29% per year. By comparison, manufacturers’ net drug sales grew at an average rate of less than 5% over the same period.
Consequently, the 340B program has grown to account for at least 6% of the total U.S. drug market.
Here’s another uncomfortable fact: Nearly all of the billions in 340B discounts have accrued to hospitals. Yet hospitals' charity care has dropped by almost $8 billion amid the 340B program’s astounding growth.
Read on for the latest details and ponder who really benefits from the 340B program's growth.
Read more »
Source: Post feed
